MedTrace Logo

An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD

NCT06022744 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-09-05

No results posted yet for this study

Summary

To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.

Conditions

  • To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD

Interventions

DRUG

LX109

LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-09-30
Completion
2027-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06022744 on ClinicalTrials.gov